Published April 28, 2026 | Version v1
Preprint Open

Topical Imiquimod-Calcipotriol Combination for Superficial Vulvar Extramammary Paget Disease

Authors/Creators

  • 1. MedicOath

Description

ClinicalTrials.gov shows completed Phase 3 trial NCT02385188 tested topical 5% imiquimod for vulvar Paget's. Lens.org patents report successful 'Topical Calcipotriol Plus Imiquimod Immunotherapy' (2023). Imiquimod activates TLR7/8 inducing local immune response while calcipotriol modulates vitamin D receptor affecting cell differentiation.

Notes

IPFS: QmUFg94Zr6sNHjJJpsthUb16HRXAso9exCBST31JLv2624. TX: 0x0c0b2c8ace9311855ed920e5b2a048824ca4e7828c826a71daa4a0bf66ac96ee. CC0.

Files

hypothesis.json

Files (389 Bytes)

Name Size Download all
md5:b9a0b8429c941210181dbcb8e41be18c
389 Bytes Preview Download